

**Ivermectin Formulation**

Version 4.3      Revision Date: 30.09.2023      SDS Number: 6097527-00013      Date of last issue: 04.04.2023  
Date of first issue: 30.06.2020

---

**1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Ivermectin Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : 50 Tuas West Drive  
Singapore - Singapore 638408

Telephone : +1-908-740-4000

Emergency telephone number : 65 6697 2111 (24/7/365)

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

**2. HAZARDS IDENTIFICATION****GHS Classification**

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Central nervous system)

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 1

**GHS label elements**

Hazard pictograms :



Signal word : Warning

Hazard statements : H371 May cause damage to organs (Central nervous system) if swallowed.  
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

## Ivermectin Formulation

Version 4.3      Revision Date: 30.09.2023      SDS Number: 6097527-00013      Date of last issue: 04.04.2023  
Date of first issue: 30.06.2020

---

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements :

**Prevention:**

P260 Do not breathe mist or vapours.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P273 Avoid release to the environment.

**Response:**

P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

---

**3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Ivermectin	70288-86-7	$\geq 1$ - $< 2.5$
2,6-Di-tert-butyl-p-cresol	128-37-0	$\geq 0.25$ - $< 1$

---

**4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do so by medical personnel.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.

Most important symptoms : May cause damage to organs if swallowed.

---

## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

and effects, both acute and delayed  
 Protection of first-aiders : May cause damage to organs through prolonged or repeated exposure if swallowed.  
 : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).  
 Notes to physician : Treat symptomatically and supportively.

---

**5. FIREFIGHTING MEASURES**

Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.  
 Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
 Use personal protective equipment.

---

**6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
 Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
 Prevent further leakage or spillage if safe to do so.  
 Prevent spreading over a wide area (e.g. by containment or oil barriers).  
 Retain and dispose of contaminated wash water.  
 Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
 For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
 Clean up remaining materials from spill with suitable absorbent.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

## Ivermectin Formulation

Version 4.3      Revision Date: 30.09.2023      SDS Number: 6097527-00013      Date of last issue: 04.04.2023  
Date of first issue: 30.06.2020

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ivermectin	70288-86-7	TWA	30 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	300 µg/100 cm <sup>2</sup>	Internal
2,6-Di-tert-butyl-p-cresol	128-37-0	PEL (long term)	10 mg/m <sup>3</sup>	SG OEL
		TWA (Inhalable fraction and vapor)	2 mg/m <sup>3</sup>	ACGIH

- Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

tainment devices).  
Minimize open handling.

**Personal protective equipment**

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

**9. PHYSICAL AND CHEMICAL PROPERTIES**

- Appearance : oily
- Colour : light yellow
- Odour : characteristic
- Odour Threshold : No data available
- pH : No data available
- Melting point/freezing point : No data available
- Initial boiling point and boiling range : 167.5 °C

**Ivermectin Formulation**

Version 4.3      Revision Date: 30.09.2023      SDS Number: 6097527-00013      Date of last issue: 04.04.2023  
Date of first issue: 30.06.2020

---

Flash point : 219.2 °C

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : 0.88 - 0.92

Density : No data available

Solubility(ies)  
Water solubility : practically insoluble

Partition coefficient: n-octanol/water : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

---

**10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.  
Chemical stability : Stable under normal conditions.  
Possibility of hazardous reactions : Can react with strong oxidizing agents.

## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

Conditions to avoid : None known.  
Incompatible materials : Oxidizing agents  
Hazardous decomposition products : No hazardous decomposition products are known.

---

**11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****Ivermectin:**

Acute oral toxicity : LD50 (Rat): 50 mg/kg  
LD50 (Mouse): 25 mg/kg  
LD50 (Monkey): > 24 mg/kg  
Target Organs: Central nervous system  
Symptoms: Vomiting, Dilatation of the pupil  
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : LC50 (Rat): 5.11 mg/l  
Exposure time: 1 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): 406 mg/kg  
LD50 (Rat): > 660 mg/kg

**2,6-Di-tert-butyl-p-cresol:**

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg  
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Ivermectin Formulation**

Version 4.3      Revision Date: 30.09.2023      SDS Number: 6097527-00013      Date of last issue: 04.04.2023  
Date of first issue: 30.06.2020

---

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Ivermectin:**

Species : Rabbit  
Result : No skin irritation

**2,6-Di-tert-butyl-p-cresol:**

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Ivermectin:**

Species : Rabbit  
Result : Mild eye irritation

**2,6-Di-tert-butyl-p-cresol:**

Species : Rabbit  
Result : No eye irritation  
Method : OECD Test Guideline 405  
Remarks : Based on data from similar materials

**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Ivermectin:**

Exposure routes : Dermal  
Species : Humans  
Result : Does not cause skin sensitisation.

**2,6-Di-tert-butyl-p-cresol:**

Test Type : Human repeat insult patch test (HRIPT)  
Exposure routes : Skin contact  
Species : Humans  
Result : negative



**Ivermectin Formulation**

Version 4.3      Revision Date: 30.09.2023      SDS Number: 6097527-00013      Date of last issue: 04.04.2023  
Date of first issue: 30.06.2020

---

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Ivermectin:**

Genotoxicity in vitro      :    Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Test system: human diploid fibroblasts  
Result: negative

Test Type: Mouse Lymphoma  
Result: negative

**2,6-Di-tert-butyl-p-cresol:**

Genotoxicity in vitro      :    Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo      :    Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****Ivermectin:**

Species                      :    Rat  
Application Route        :    Oral  
NOAEL                      :    1.5 mg/kg body weight  
Result                      :    negative  
Remarks                  :    Based on data from similar materials

Species                      :    Mouse  
Application Route        :    Oral  
NOAEL                      :    2.0 mg/kg body weight  
Result                      :    negative  
Remarks                  :    Based on data from similar materials

## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

**2,6-Di-tert-butyl-p-cresol:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	22 Months
Result	:	negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Ivermectin:**

Effects on fertility	:	Test Type: Fertility Species: Rat Application Route: Oral Fertility: NOAEL: 0.6 mg/kg body weight Result: Animal testing did not show any effects on fertility.
Effects on foetal development	:	Test Type: Development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses
		Test Type: Development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 0.4 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected. Remarks: The mechanism or mode of action may not be relevant in humans.
		Test Type: Development Species: Rabbit Application Route: Oral Result: Teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

**2,6-Di-tert-butyl-p-cresol:**

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat

## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

Application Route: Ingestion  
Result: negative

**STOT - single exposure**

May cause damage to organs (Central nervous system) if swallowed.

**Components:****Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs.

**STOT - repeated exposure**

May cause damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

**Components:****Ivermectin:**

Target Organs : Central nervous system  
Assessment : Causes damage to organs through prolonged or repeated exposure.

**2,6-Di-tert-butyl-p-cresol:**

Assessment : No significant health effects observed in animals at concentrations of 100 mg/kg bw or less.

**Repeated dose toxicity****Components:****Ivermectin:**

Species : Dog  
NOAEL : 0.5 mg/kg  
LOAEL : 1 mg/kg  
Application Route : Oral  
Exposure time : 14 Weeks  
Target Organs : Central nervous system  
Symptoms : Dilatation of the pupil, Tremors, Lack of coordination, anorexia

Species : Monkey  
NOAEL : 1.2 mg/kg  
Application Route : Oral  
Exposure time : 2 Weeks  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 0.4 mg/kg  
LOAEL : 0.8 mg/kg  
Application Route : Oral  
Exposure time : 3 Months

**Ivermectin Formulation**

Version 4.3      Revision Date: 30.09.2023      SDS Number: 6097527-00013      Date of last issue: 04.04.2023  
Date of first issue: 30.06.2020

---

Target Organs : spleen, Bone marrow, Kidney

**2,6-Di-tert-butyl-p-cresol:**

Species : Rat  
NOAEL : 25 mg/kg  
Application Route : Ingestion  
Exposure time : 22 Months

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Ivermectin:**

Skin contact : Remarks: Can be absorbed through skin.  
Eye contact : Remarks: May irritate eyes.  
Ingestion : Symptoms: Drowsiness, Dilatation of the pupil, Tremors, Vomiting, anorexia, Lack of coordination

---

**12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Ivermectin:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.003 mg/l  
Exposure time: 96 h  
  
LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0048 mg/l  
Exposure time: 96 h  
  
Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.000025 mg/l  
Exposure time: 48 h  
  
Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9.1 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
  
NOEC (Pseudokirchneriella subcapitata (green algae)): 9.1 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201  
  
M-Factor (Acute aquatic toxicity) : 10,000  
M-Factor (Chronic aquatic toxicity) : 10,000

## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

**2,6-Di-tert-butyl-p-cresol:**

- Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 0.57 mg/l  
Exposure time: 96 h  
Method: Directive 67/548/EEC, Annex V, C.1.
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.48 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201
- M-Factor (Acute aquatic toxicity) : 1
- Toxicity to fish (Chronic toxicity) : NOEC (Oryzias latipes (Japanese medaka)): 0.053 mg/l  
Exposure time: 30 d  
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.316 mg/l  
Exposure time: 21 d
- M-Factor (Chronic aquatic toxicity) : 1
- Toxicity to microorganisms : EC50: > 10,000 mg/l  
Exposure time: 3 h  
Method: OECD Test Guideline 209

**Persistence and degradability****Components:****Ivermectin:**

- Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 50 %  
Exposure time: 240 d

**2,6-Di-tert-butyl-p-cresol:**

- Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 4.5 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301C

## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

**Bioaccumulative potential****Components:****Ivermectin:**

Bioaccumulation : Bioconcentration factor (BCF): 74

Partition coefficient: n-octanol/water : log Pow: 3.22

**2,6-Di-tert-butyl-p-cresol:**

Bioaccumulation : Species: Cyprinus carpio (Carp)  
Bioconcentration factor (BCF): 330 - 1,800

Partition coefficient: n-octanol/water : log Pow: 5.1

**Mobility in soil**

No data available

**Other adverse effects**

No data available

**13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

**14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

**IATA-DGR**

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(Ivermectin, 2,6-Di-tert-butyl-p-cresol)

Class : 9

Packing group : III

Labels : Miscellaneous

## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

Packing instruction (cargo aircraft) : 964  
Packing instruction (passenger aircraft) : 964  
Environmentally hazardous : yes

**IMDG-Code**

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(Ivermectin, 2,6-Di-tert-butyl-p-cresol)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable for product as supplied.

**Special precautions for user**

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

**15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture****Workplace Safety and Health Act and Workplace Safety and Health (General Provisions) Regulations: This product is subjected to the SDS, labelling, PEL and other requirements in the Act/Regulations.**

Environmental Protection and Management Act and : Not applicable  
Environmental Protection and Management (Hazardous Substances) Regulations

Fire Safety (Petroleum and Flammable Materials) : Not applicable  
Regulations

**The components of this product are reported in the following inventories:**

AICS : not determined  
DSL : not determined  
IECSC : not determined

---

**16. OTHER INFORMATION**

## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

Revision Date : 30.09.2023

**Further information**

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 SG OEL : Singapore. Workplace Safety and Health (General Provisions) Regulations - First Schedule Permissible Exposure Limits of Toxic Substances.

ACGIH / TWA : 8-hour, time-weighted average  
 SG OEL / PEL (long term) : Permissible Exposure Level (PEL) Long Term

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only



## Ivermectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.3	30.09.2023	6097527-00013	Date of first issue: 30.06.2020

---

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SG / EN